Table 1. Features of individual included research.
| Research | Year | Type of tumor | Patients’ No. | M / F | Median age (range) (year) | Cut-off value | PDGFR-β+ fibroblast: (H/L) | TNM stage | Median follow-up (months) | Clinical outcome | Quality score (NOS) |
| Park, C.K. et al [11] | 2016 | Breast cancer | 524 | 0/524 | <50: 55.8%; ≥50: 44.2% | ≥ 10% of the stroma /HPF | 153/489 | I - III | NR | OS, DFS | 8 |
| Park, S.Y. et al [12] | 2015 | Breast cancer | 642 | 0/642 | ≤50: 60.3%; >50: 39.7% |
≥ 10% of the stroma /HPF | 153/489 | I - III | 68.3 ± 30.1 | OS, DFS | 8 |
| Kim, H.M. et al [13] | 2016 | Malignant phyllodes tumor of breast | 16 | 0/16 | 47.6 ± 12.9 | ≥ 30% of the stroma /HPF | 5/11 | NR | NR | OS, DFS | 8 |
| Jung, Y.Y. et al [14] | 2015 | Breast cancer | 642 | 0/642 | ≤50: 60.3%; >50: 39.7% |
≥ 10% of the stroma /HPF | 23/619 | I - III | 68.3 ± 30.1 | OS, DFS | 7 |
| Paulsson, J. et al [15] | 2009 | Breast cancer | 289 | 0/289 | 64.2 (27, 96) | ≥ 10% of stromal fibroblasts /HPF | 100/189 | I - III | 106 (0, 207) | OS, DFS | 8 |
| Kilvaer, T.K. et al [16] | 2019 | NSCLC | 513 | 343/170 | <65: 42.5%; ≥65: 57.5% |
Score ≥2 | 202/311 | IA - IIIB | NR | OS | 7 |
| Kanzaki, R. et al [17] | 2018 | NSCLC | 92 | 78/14 | 60.2 | ≥ 5% of the stroma /HPF | 65/27 | IA - IV | 187 (48, 260) | OS, DFS | 8 |
| Donnem, T. et al [18] | 2008 | NSCLC | 335 | 255/80 | 67 (28, 85) | Score ≥ 2.5 | 69/262 | I - IIIA | 96 (10, 179) | OS | 7 |
| Kilvaer, T.K. et al [19] | 2018 | NSCLC | 499 | 161/338 | <65: 42.9%; ≥65: 57.1% |
≥ 10% of the stroma /HPF | 199/300 | IA - IIIA | 48.0 (1, 137) | OS | 7 |
| Chu, J.S. et al [20] | 2013 | Hepatic carcinoma | 93 | 77/16 | ≤50: 33.3%; >50: 66.7% |
≥ 50% of stroma /10HPF | 18/75 | III | (1, 58) | OS | 6 |
| Zhang, X.F. et al [21] | 2017 | Intrahepatic cholangiocarcinoma | 41 | NR | NR | ≥ 20% of the stroma /HPF | 33/8 | I - IV | 15.7 (1.3, 63.2) | OS | 6 |
| Chen, L. et al [22] | 2011 | Hepatic carcinoma | 63 | 59/4 | 48.9 (30, 73) | ≥ 26% of the stroma /HPF | 43/20 | I - IV | 46.7 (40.3, 62.1) | OS, DFS | 7 |
| Sayaka, Y. et al [23] | 2012 | Pancreatic adenocarcinoma | 26 | 18/8 | 61.5 (45, 81) | NR | 13/13 | I - IVB | NR | OS | 6 |
| Kurahara, H. et al [24] | 2016 | Pancreatic cancer | 120 | 71/49 | ≤70: 60.8%; >70: 39.2% |
score > 2 | 59/61 | NR | 29.2 | OS | 6 |
| Hagglof, C. et al [25] | 2010 | Prostate cancer | 244 | 244/0 | 74 (51, 95) | mean density ≥1.0 | 66/178 | NR | (1, 300) | OS | 7 |
| Nordby, Y. et al [26] | 2017 | Prostate cancer | 529 | 529/0 | 62 (47, 75) | mean density ≥1.50 | 262/267 | I - IV | 148.8 (18, 240) | DFS | 6 |
| Frodin, M. et al [27] | 2017 | Renal cell carcinoma | 287 | 162/125 | (37, 89) | NR | 144/143 | I - IV | NR | OS | 8 |
| Shim, M. et al [28] | 2015 | Renal cell carcinoma | 758 | 536/222 | 55 (47, 64) | ≥ 33% of the stroma /HPF | 302/456 | I - II | 29.5 (21.5, 39.6) | DFS | 7 |
| Corvigno, S. et al [29] | 2016 | Ovarian cancer | 154 | 0/154 | 60 (22, 84) | ≥ 10% of the stroma /HPF | 79/75 | I - IV | 28 (0.03, 162.5) | OS | 7 |
| Mezheyeuski, A. et al [30] | 2016 | Colorectal cancer | 372 | 182/190 | (18, 75) | ≥ 50% of the stroma /HPF | NR | IV | 9 (7.8, 10.2) | OS | 7 |
| Yonemori, K. et al [31] | 2011 | Angiosarcoma | 34 | 9/25 | 68 (16, 96) | Score ≥1 | 30/4 | I - III | 26.7 (0.3, 152.6) | OS | 7 |
| Ha, S.Y. et al [32] | 2014 | Esophageal squamous cell carcinoma | 116 | 112/4 | <65: 26.7%; ≥65: 73.3% |
≥ 50% of the stroma /HPF | 63/53 | I - IV | 30 (0, 108) | OS, DFS | 6 |
| Moreno, L. et al [33] | 2013 | Ependymoma | 24 | 15/9 | (1.5, 64.9) | ≥ 50% of the stroma /HPF | 7/17 | IV | 32.3 (2.1, 59.1) | OS | 6 |
| Sun, W.Y. et al [34] | 2015 | Thyroid papillary carcinoma | 339 | NR | NR | ≥ 50% of the stromal cells /HPF | 72/267 | NR | NR | OS, DFS | 6 |
OS: overall survival; DFS: disease-free survival; TNM, Tumor, Lymph Node, Metastasis; NR: not reported; HPF: high power field. M: male; F: female.